Latest AtaiBeckley News & Updates

See the latest news and media coverage for AtaiBeckley. We track all announcements, press releases, and industry mentions in real time, all in one place.

AtaiBeckley

Mental health therapeutics developer

ataibeckley.com

Headquarters: New York, United States
Company type: Public company
Number of employees: 100–200
Industry: Pharmaceuticals

Last updated Today

Latest news about AtaiBeckley

In short: AtaiBeckley was acquired by Eli Lilly for $2.8 billion to bolster its mental health pipeline following successful clinical trial results.

Company announcements

July 16 AtaiBeckley

AtaiBeckley acquired by Lilly for $2.8 billion

The deal includes potential milestone payments and expands Lilly's neuroscience pipeline for treatment-resistant depression.

July 6 AtaiBeckley

AtaiBeckley completes enrollment in VLS-01 Phase 2b TRD trial

Topline data due Q4 2026; intends to start Phase 3 for major depressive disorder.

April 22 AtaiBeckley

AtaiBeckley announces additional Phase 2a results for EMP-01

The trial demonstrated clinically meaningful reductions in SAD symptoms and high responder rates with no serious adverse events.

April 8 AtaiBeckley

AtaiBeckley's BPL-003 shows rapid antidepressant response in Phase 2a trial

The drug achieved 66.7% response rate by Day 2 and durable effects through Week 12, with FDA Breakthrough Therapy designation and Phase 3 initiation on track for Q2 2026.

Media coverage

August 31 Yahoo Finance

Social anxiety drugs have been floundering in the clinic. Could Eli Lilly help tip the scales?

After two notable failures, the social anxiety R&D space gained a major player when Eli Lilly agreed to acquire AtaiBeckley this year.

August 28 The AI Journal

AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. – ATAI

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the...

August 25 Seeking Alpha

Compass Pathways: Still A Buy, But The Exit Just Got Complicated

Compass Pathways stays a Buy, but Eli Lilly’s AtaiBeckley deal raises competition and funding risks. Click to get key ...

August 23 Börse Global

Atai Beckley Stock: Oppenheimer downgrades to Market Perform

Despite ongoing merger with Eli Lilly, analysts lower their ratings. Investors await shareholder vote and review the ...

Never miss news about AtaiBeckley

Track AtaiBeckley and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

AtaiBeckley competitors & trending companies

Browse news for competitors to AtaiBeckley and other trending companies.